2019
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater E, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal Of The American Academy Of Dermatology 2019, 82: 161-201. PMID: 31703821, DOI: 10.1016/j.jaad.2019.08.049.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAnthralinBiological ProductsCalcineurin InhibitorsCardiovascular DiseasesChildChild, PreschoolCoal TarComorbidityCyclosporineDermatologic AgentsDyslipidemiasEvidence-Based MedicineHumansInfantInfant, NewbornInflammatory Bowel DiseasesInsulin ResistanceMental HealthMetabolic SyndromeMethotrexateNicotinic AcidsObesityPhotochemotherapyPsoriasisRetinoidsConceptsPediatric patientsDermatology–National Psoriasis Foundation guidelinesTreatment of psoriasisImportant clinical questionsEvidence-based recommendationsJoint American AcademyPsoriasis managementInflammatory diseasesFoundation guidelinesClinical questionsPatientsAmerican AcademyPsoriasisProvider interactionsGuideline sectionsUnique physiologyGuidelinesPharmacokineticsDiseaseCareMultisystem
2009
Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation
Menon K, Van Voorhees A, Bebo B, Gladman D, Hsu S, Kalb R, Lebwohl M, Strober B, Foundation P. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. Journal Of The American Academy Of Dermatology 2009, 62: 291-299. PMID: 19646777, DOI: 10.1016/j.jaad.2009.03.047.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV-associated psoriasisPotential adverse eventsPsoriatic arthritisAdverse eventsHIV infectionSevere diseaseTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsNational Psoriasis Foundation Medical BoardFirst-line therapeutic agentsPlacebo-controlled trialSecond-line treatmentInfectious disease specialistsSafety of treatmentNational Psoriasis FoundationBenefits of treatmentMedical boardsOral retinoidsTopical therapyModerate diseaseCase seriesDisease specialistsImmunodeficiency virusTreatment options